Daily ReportOct 8, 2026
Sepsis, October 8 edition
We read 34 papers and selected 3.
Summary
Today’s strongest sepsis studies advanced precision medicine in three complementary directions: proteomic subphenotyping of sepsis-associated acute kidney injury, kidney-targeted exosome therapy in a clinically relevant porcine model, and disease-specific glycemic targets supported by a large ICU cohort and randomized-trial network meta-analysis. Collectively, these studies emphasize biological heterogeneity, mechanistically targeted treatment, and individualized supportive care rather than uniform sepsis protocols.
Research Themes
- Precision subphenotyping and biomarker-guided therapy
- Mechanism-based treatment of sepsis-associated acute kidney injury
- Disease-specific glycemic management in critical illness
Selected Articles
1. Plasma proteomics defines two reproducible subphenotypes of sepsis-associated acute kidney injury with distinct outcomes.
Using ensemble clustering across three independent patient groups, the study identified two reproducible plasma-proteomic subphenotypes of sepsis-associated acute kidney injury. The inflammatory subtype had higher mortality and morbidity, while a seven-protein panel reproduced the classification in separate cohorts; exploratory randomized-trial data suggested benefit from ilofotase alfa in the inflammatory subtype.
Impact: This paper directly addresses a major reason for failed sepsis trials: biological heterogeneity within clinically defined syndromes. It links a reproducible molecular classification to outcomes and a potential treatment interaction, providing a concrete framework for biomarker-guided clinical trials.
Clinical Implications: A seven-protein assay could eventually support risk stratification and selection of patients for targeted therapies such as ilofotase alfa. The findings are not yet sufficient for routine clinical use and require prospective validation with analytically standardized testing and treatment-stratified trials.
Key Findings
- Sepsis-associated acute kidney injury contained two reproducible plasma-proteomic subphenotypes across three independent patient groups.
- The inflammatory subphenotype showed broad activation of inflammation, metabolism, and oxidative stress and was associated with higher mortality, more complications, and fewer ICU-free days.
- A seven-protein panel accurately reproduced the subphenotypes in separate cohorts, and exploratory randomized-trial data suggested benefit from ilofotase alfa in the inflammatory subtype.
Methodological Strengths
- Use of ensemble proteomic clustering across three independent patient groups improves reproducibility and reduces dependence on a single cohort.
- The study combined molecular classification, a simplified biomarker panel, external cohort assessment, and treatment-response exploration.
Limitations
- The treatment-response evidence for ilofotase alfa is exploratory and does not establish efficacy for clinical practice.
- The abstract does not provide the cohort sizes, assay details, or complete performance characteristics needed to assess implementation of the seven-protein test.
Future Directions: Prospective multicenter validation should confirm the subphenotypes using standardized assays, determine whether classification changes over time, and test biomarker-guided treatment allocation in adequately powered randomized trials.
Sepsis is the leading cause of acute kidney injury in critically ill patients, and this complication carries a high risk of death. The biology underlying it varies between patients, which may explain why treatments have not succeeded. Here we show, using an ensemble method that groups patients by patterns across hundreds of blood proteins in three independent groups of patients, that sepsis-associated acute kidney injury comprises two reproducible subphenotypes. One subphenotype shows widespread activation of inflammation, metabolism, and oxidative stress; the other shows a quieter profile. Patients in the inflammatory subtype have higher mortality, more complications, and fewer days alive and out of the intensive care unit.
2. Fibroblastic Reticular Cell-Derived and CD5L-Enriched Exosomes Remodel Renal Lipid Metabolism in Porcine Sepsis-Associated Acute Kidney Injury.
In a clinically relevant porcine model of lipopolysaccharide-induced sepsis-associated acute kidney injury, kidney-targeted engineered exosomes improved systemic hemodynamics, renal microvascular perfusion, and kidney injury indices. Treatment reduced renal lipid-droplet and acylcarnitine accumulation and was associated with CD5L–fatty acid synthase interaction, AMPK-ACC-CPT1A signaling, improved mitochondrial bioenergetics, preserved mitochondrial morphology, and reduced tubular-cell pyroptosis.
Impact: The study provides mechanistic and therapeutic evidence that renal lipid-metabolism failure is a modifiable component of sepsis-associated acute kidney injury. Use of a large-animal model and kidney-targeted engineered exosomes strengthens translational relevance beyond conventional cell or small-animal experiments.
Clinical Implications: The findings support development of kidney-targeted exosome therapy as a potential treatment for sepsis-associated acute kidney injury. Clinical translation will require rigorous assessment of manufacturing consistency, biodistribution, immunogenicity, thrombosis risk, dose, and efficacy in human sepsis.
Key Findings
- Kidney-targeted fibroblastic reticular cell-derived and CD5L-enriched exosomes improved systemic hemodynamics, renal microvascular perfusion, and kidney injury indices in septic pigs.
- Treatment reduced renal lipid-droplet and acylcarnitine accumulation and was associated with remodeling of short-chain fatty acid and AMPK-ACC-CPT1A pathways.
- Exosome therapy improved mitochondrial bioenergetic indices and morphology and reduced markers of tubular-cell pyroptosis.
Methodological Strengths
- Use of a porcine sepsis-associated acute kidney injury model provides greater physiological and translational relevance than many rodent models.
- The study integrated engineered therapeutic delivery, organ-level outcomes, multiomic analysis, and cellular mechanistic assessment.
Limitations
- The study used a lipopolysaccharide-induced porcine model, which may not reproduce the pathogen diversity, source control, and temporal heterogeneity of human sepsis.
- The abstract does not report sample size, duration of observation, or comparative safety outcomes in sufficient detail for clinical translation.
Future Directions: Further studies should compare exosomes with standard supportive care and other experimental therapies, define dose-response and treatment windows, assess long-term renal outcomes, and establish scalable good-manufacturing-practice production before first-in-human trials.
BACKGROUND: Sepsis-associated AKI is a life-threatening condition associated with profound metabolic dysfunction, including impaired mitochondrial fatty acid handling. Therapies capable of reversing this metabolic dysfunction remain lacking. Using a clinically relevant porcine model, we investigated whether kidney-targeted fibroblastic reticular cell-derived and CD5L-enriched exosomes could ameliorate sepsis-associated AKI. METHODS: We generated engineered exosomes derived from fibroblastic reticular cells or CD5L-overexpressing cells and functionalized them with the kidney-targeting LTH peptide. Therapeutic efficacy and safety were evaluated in a porcine model of lipopolysaccharide-induced sepsis-associated AKI. Integrated multiomic and cellular analyses were performed to examine the associated molecular pathways. RESULTS: In septic pigs, both fibroblastic reticular cell-derived and CD5L-enriched exosomes improved systemic hemodynamics, renal microvascular perfusion, and kidney injury indices. Exosome treatment reduced renal lipid-droplet and acylcarnitine accumulation. CD5L interacted with fatty acid synthase, and treatment was associated with changes in short-chain fatty acids and AMPK-ACC-CPT1A signaling.
3. Disease-Specific Optimal Blood Glucose Control Strategies in Critically Ill Patients: Retrospective Cohort Study and Network Meta-analysis.
This study combined a large MIMIC-IV cohort with a network meta-analysis of 35 randomized controlled trials to examine disease-specific glucose targets. Intermediate-strict control at 110–150 mg/dL was associated with the lowest 28-day mortality in sepsis, whereas strict control appeared favorable in neurological illness; network meta-analysis results supported intermediate-strict control as the highest-ranked strategy for sepsis, although pairwise differences were not statistically significant.
Impact: The paper challenges the one-size-fits-all glucose target paradigm by showing that the apparent optimal range differs between sepsis, cardiac disease, and neurological illness. Its combination of a large observational dataset and randomized-trial synthesis provides clinically relevant, hypothesis-generating evidence for individualized glycemic management.
Clinical Implications: For sepsis, avoiding both very tight control and marked hyperglycemia may be reasonable, with 110–150 mg/dL as a hypothesis-supported target range. This should not replace guideline-based insulin protocols because observational confounding, heterogeneity among trials, and uncertainty in the cardiac subgroup remain substantial.
Key Findings
- The retrospective analysis included 21,119 patients with sepsis, 16,957 with cardiac disease, and 4,708 with neurological disease.
- In sepsis, intermediate-strict glucose control of 110–150 mg/dL was associated with lower 28-day mortality than strict control of 80–110 mg/dL or liberal control of 150–180 mg/dL.
- A network meta-analysis of 35 randomized controlled trials ranked intermediate-strict control highest for sepsis, while strict control ranked highest for neurological disorders; pairwise differences were not statistically significant.
Methodological Strengths
- The study triangulated findings from a large critical-care database and a network meta-analysis of randomized controlled trials.
- Disease-specific stratification directly tests the clinical assumption that glucose targets should depend on underlying pathophysiology.
Limitations
- The retrospective cohort is vulnerable to confounding by illness severity, treatment selection, nutrition, corticosteroid use, and measurement practices.
- Network meta-analysis rankings do not establish superiority when pairwise differences are not statistically significant, and optimal targets remained uncertain in cardiac disease.
Future Directions: Prospective pragmatic trials should compare disease-specific glucose targets in sepsis, incorporate hypoglycemia and glycemic variability as safety outcomes, and examine whether targets should be further individualized by shock phenotype, diabetes status, nutrition, and corticosteroid exposure.
BACKGROUND: Optimal glucose targets for critically ill patients are likely to vary by underlying condition, yet a 'one-size-fits-all' approach persists. AIM: Determining disease-specific glucose thresholds may help achieve the lowest mortality rates. STUDY DESIGN: This study combined a retrospective cohort analysis of the Medical Information Mart for Intensive Care-IV (MIMIC-IV) database with a frequentist network meta-analysis (NMA) of randomized controlled trials (RCTs). The glucose control targets, measured by time-weighted average glucose (TWAg), were categorized into four strata: strict, intermediate strict, liberal and very liberal control. RESULTS: The retrospective analysis included 21 119 sepsis, 16 957 cardiac and 4708 neurological patients. In both sepsis and cardiac patients, compared with the intermediate strict control group (110-150 mg/dL, reference), both the strict (80-110 mg/dL: HR 1.10/1.26, both p < 0.05) and liberal (150-180 mg/dL: HR 1.38/1.78, both p < 0.05) control groups showed significantly higher 28-day mortality. In contrast, among neurological patients, strict control conferred a survival benefit (HR 0.76, p = 0.013).